InvestorsHub Logo
Followers 57
Posts 5700
Boards Moderated 0
Alias Born 12/13/2004

Re: freethemice post# 125649

Monday, 06/03/2013 11:00:31 AM

Monday, June 03, 2013 11:00:31 AM

Post# of 346002
Breast cancer results = OUTSTANDING! Pancreatic cancer results = lower ECOG results looks good. Second line NSCLC = GOING INTO PHASE III!

This is what potential partners have been looking at for some time now. They may also be looking at the front line NSCLC and liver cancer data. Anyone care to estimate market potential in first and second line NSCLC, breast cancer, pancreatic and liver cancer?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News